GlobalData on MSN

NMD Pharma to progress CMT pill despite primary endpoint miss

The biotech is now banking on secondary data signals as it progresses ignaseclant to late-stage trials in Charcot-Marie-Tooth ...
The Manila Times

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel ...
Pharmabiz

Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS

Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...

Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher diseaseIn the LEAP2MONO phase 3 study, venglustat, dosed ...

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...
Monthly Prescribing Reference

Benralizumab Misses Primary Endpoint in COPD Trial

While treatment with benralizumab showed numerical improvement over placebo for the primary endpoint, the result was not statistically significant. A phase 3 trial evaluating benralizumab for the ...
Benzinga.com

Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive ...
Seeking Alpha

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases ...
Nasdaq

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically ...

CORRECTION -- Privo Technologies Announces Milestone in PRV211 Arm of CLN-004 Clinical Trial: Primary Endpoint Met; No Serious Adverse Events Reported

PRV211 represents Arm 2 of Privo's CLN-004 clinical program. Combined with Arm 1's achievement of its primary efficacy endpoint and Arm 3's dosing initiation, the program demonstrates continued ...
Medscape

CONCERTO: Laquinimod for Relapsing-Remitting MS Fails to Meet Primary Endpoint

Topline results from the phase 3 CONCERTO trial show that the oral treatment for relapsing-remitting multiple sclerosis (RRMS) did not meet its primary endpoint, according to an announcement from the ...

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK ...